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MicroRNAs have recently emerged as key regulators of gastric cancers. Here we found that miR-145,
miR-133a and miR-133b were down-regulated in gastric cancer tissues and cell lines. Overexpres-
sion of miR-145, miR-133a and miR-133b induced G1 cell cycle arrest and inhibited cell prolifera-
tion, migration and invasion in vitro. MiR-145, miR-133a and miR-133b targeted the transcription
factor SP1, knockdown of which reduced the expression of MMP-9 and Cyclin D1 that were involved
in cell growth and invasion. Thus, our ﬁndings demonstrated for the ﬁrst time that miR-145, miR-
133a and miR-133b suppressed the proliferation, migration, invasion and cell cycle progression of
gastric cancer cells through decreasing expression of Sp1 and its downstream proteins.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer is one of the most common cancers in the world.
Despite improvement in early diagnosis, it is still considered to be
a fatal disease [1]. It is increasingly recognized that gastric carcino-
genesis is a complex, multi-step and multi-factorial process in
which many environmental and genetic factors are implicated.
Studies have shown that abnormalities of various oncogenes,
tumor suppressor genes, growth factors and transcription fac-
tors may play important roles in tumor pathogenesis [2–4].
These molecular changes could affect downstream signal path-
ways which involved in the control of cell growth and
differentiation.
Among them, the transcription factor speciﬁcity protein 1 (Sp1)
has been considered to have an association with gastric cancer. Sp1
has GC-rich promoter sequences and regulates transcriptionthrough these GC boxes. The human Sp1 gene maps to 12q13.1
and encodes a protein of 785 amino acids [5]. It is a well-character-
ized, sequence-speciﬁc, DNA-binding protein that is involved in
many cellular process [5]. As a transcription factor, Sp1 can regu-
late thousands of genes, such as Cyclin D1, Vascular endothelial
growth factor (VEGF), Phosphatase 2A (PP2A) and Matrix metallo-
proteinase (MMP). Thus, Sp1 is important for a variety of physio-
logical processes, including cell cycle progression, angiogenesis,
cell migration and invasion. It can affect tumorigenesis by modu-
lating the expression of its target genes [6–9].
MicroRNAs (miRNA) are short non-coding RNAs with a length of
19–22 nucleotides that function as post-transcriptional regulators
by directly cleaving target messenger RNA (mRNA) or translational
repression [10]. Aberrant miRNAs in gastric cancer could regulate
genes involved in proliferation, metastasis and invasion [11]. Re-
cent studies have investigated that miRNAs played an important
role in regulating cell survival signal pathways involving Sp1 in dif-
ferent cancers [12–14]. However, the underlying mechanism is not
completely clear.
In this study, we validated the differential expression of miR-145,
miR-133a and miR-133b in gastric cancer and investigated the
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cell cycle progression. Furthermore, Sp1 was identiﬁed as a target
gene of these miRNAs and participated in cell proliferation, migra-
tion, invasion and cell cycle progression through its downstream
proteins. Thus, miR-145, miR-133a and miR-133b might act as tu-
mor suppressors and serve as potential therapeutic targets in gas-
tric cancer.2. Materials and methods
2.1. Gastric tissues collection
Twenty-six paired tissue specimens of gastric cancer and
matched normal tissues were obtained from surgery patients be-
tween 2011 and 2012 at First Afﬁliated Hospital of Nanjing Medical
University. The study was approved by Institutional Review Boards
of the First Afﬁliated Hospital of Nanjing Medical University and
informed consent was taken from all patients. All the tissues were
histopathologically conﬁrmed and kept at 80 C for further RNA
extraction.
2.2. RNA isolation and qRT-PCR
Total RNA from tissues and cells were isolated using Trizol
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. The concentration and purity of the total RNA were
evaluated using the ultraviolet spectrophotometer. Total RNA
was stored at 80 C until analysis.
The speciﬁc primers of reverse transcription (RT) and polymer-
ase chain reaction (PCR) from Bulge-Loop™ miRNA qRT-PCR Pri-
mer Set (RiboBio, China) were used to amplify miRNAs. The
amounts of PCR products were determined by the level of ﬂuores-
cence in emitted by SYBR Green (SYBR Premix Ex Taq™ II, TaKa-
Ra). RT and PCR was performed as described previously [15]. RT
reaction was incubated at 42 C for 60 min followed by 70 C for
10 min. The qRT-PCR was performed on 7900HT real-time PCR sys-
tem (Applied Biosystems) at 95 C for 20 s, followed by 40 cycles
of 95 C for 10 s, 60 C for 20 s and then 70 C for 10 s. The melt-
ing analysis was added ﬁnally to assess the speciﬁcity of PCR
products.
2.3. Cell culture and transfection
The human gastric cancer cell lines SGC7901, MKN45 and
BCG823 and human gastric mucosal epithelial cell line GES-1 (all
obtained from Biosis Biotechnology Co., Ltd., Shanghai, China) were
cultured in RPMI-1640 medium supplemented with 10% fetal calf
serum (Gibco-BRL, Grand Island, NY, USA). Cultures were main-
tained at 37 C in a humidiﬁed atmosphere with 5% CO2.
MiRNA mimics and their appropriate negative control (NC)
were purchased from Guangzhou RiboBio (RiboBio, Guangzhou,
China) and transfected into cells at a ﬁnal concentration of
50 nmol/L by using Lipofectamine 2000 (Invitrogen) according to
manufacturer’s instructions.2.4. Western blot analysis
SGC7901, MKN45 and BCG823 cells were ﬁrst plated in 6-well
plates (6  105 cells/well). At 72 h after transfection with miRNA
mimics, cells were subjected to Western blot as described
previously [16]. The primary antibodies against Sp1, MMP-9,
Cyclin D1 were purchased from Cell Signaling Technology
(Danvers, MA, USA). Protein levels were normalized to total GAPDH
or b-actin (Bioworld Technology, MN, USA). Fold-changes were
determined.2.5. Immunoﬂuorescence assay
Immunoﬂuorescence of gastric cancer cells was detected using
Immunoﬂuorescence Staining Kit (Beyotime Institution of Biotech-
nology, Shanghai, China). Cells were plated and ﬁxed in 4% parafor-
maldehyde. Unspeciﬁc bindings were blocked with 5% fetal bovine
serum 60 min prior to the incubation with a rabbit antibody to Sp1
(Cell Signaling Technology, MA, USA). Cells were subsequently
washed three times and further incubated with FITC-conjugated
anti-rabbit secondary antibody 1 h and stained with 5 ng/ml DAPI
to visualize the nucleus for 5 min. The results were analyzed using
a BX60 ﬂuorescence microscope (Olympus, Hamburg, Germany).
2.6. Cell cycle progression analysis
Gastric cancer cells were plated in 6-well plates and transfected
with miR-145, miR-133a, miR-133b mimics or negative control oli-
gonucleotide respectively. The effects of these miRNAs on cell cycle
progression were determined by FACS (ﬂuorescence-activated cell
sorter) analysis using the Cell Cycle and Apoptosis Analysis Kit
(Beyotime Institution of Biotechnology, Shanghai, China) according
to the recommended protocol. Ten thousand cells were counted
per sample. The data were analyzed using MultiCycle software
WinCycle32.
2.7. Dual luciferase activity assay
30UTR sequences of Sp1 that contain the predicted target site
(wild type, WT) or mutated sequences (mutant type, MUT) of
miR-145, miR-133a, miR-133b were synthesized by Guangzhou
RiboBio Co., Ltd. Human embryonic kidney cell line HEK293T cells
were plated at 1.5  105 cells/well in 24-well plates before trans-
fection. Twenty-four hours later, wild type or mutant luciferase re-
porter constructs were co-transfected into cells with miR-145,
miR-133a, miR-133b or negative control oligonucleotide by lipo-
fectamine 2000 (Invitrogen). After 24 h, luciferase activity was
measured using the Dual Luciferase Reporter Assay System (Pro-
mega, Madison, WI, USA) according to the manufacturer’s instruc-
tions. Three independent experiments were performed in
duplicate.
2.8. Cell proliferation assay
Gastric cancer cells proliferation was measured by using Cell
Counting Kit-8 (CCK8) detection kit (Dojindo, Japan). Cells with a
concentration of 5  103 per well were seeded in 96-well plates
for 24 h before transfection. For quantitation of cell viability,
10 ll CCK-8 solution was added to each well and followed an incu-
bation at 37 C for 4 h at 24 h, 48 and 72 h after transfection.
Absorbance value of each well was measured spectrophotometri-
cally at 450 nm.
2.9. Migration and invasion assay
For migration assay, 1  105 cells were plated onto 24-well Mil-
liCell chambers (Millipore, Bedford, MA, USA) with an 8-lm pore
polycarbonate membrane. For invasion assay, 1.5  105 cells were
plated pre-coated with 20 lg of Matrigel on the upper side. In both
assays, the cells were plated in medium supplemented with 0.1%
serum and the chambers were placed into 24-well plates with
medium containing 10% serum. After 24 or 48 h, invaded cells on
the lower membrane surface were ﬁxed and stained with 0.1%
crystal violet while cells that did not migrate or invade through
the pores were removed by cotton swabs. Three random ﬁelds
for each insert were counted and the results were averaged among
three independent experiments.
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All Statistical analysis was performed using SPSS15.0 software
(SPSS Inc., Chicago, IL, USA). Data are expressed as the mean ± stan-
dard deviation (S.D.) from at least three separate experiments. The
differences between means were analyzed using the Student’s
t-test and Chi-square test. A P-value <0.05 was considered to
indicate a statistically signiﬁcant difference.Fig. 1. Expression analysis of miR-145, miR-133a and miR-133b in gastric cancer tissues
miR-133b expression in normal gastric mucosa samples and malignant tissues. N, no
expression in gastric mucosal epithelial cell line (GES-1) and gastric cancer cell lines (SG
Fig. 2. Cell proliferation was analyzed by CCK8 assay in SGC7901, BCG823 and MKN45
transfection.3. Results
3.1. The expression of miR-145, miR-133a and miR-133b is down-
regulated in gastric cancer tissues and cell lines
To investigate the expression of miR-145, miR-133a and miR-
133b in gastric cancer, qRT-PCR was performed in 26 pairs of tis-
sues and 4 human gastric cell lines (SGC7901, MKN45, BCG823and gastric cancer cell lines. (A) Real-time PCR analysis of miR-145, miR-133a and
rmal; T, tumor. (B) Real-time PCR analysis of miR-145, miR-133a and miR-133b
C7901, MKN45, BCG823). ⁄P < 0.05.
cell lines. Growth curve was shown for each treatment at 0, 24, 48 and 72 h after
Fig. 3. Inhibition of tumor cell migration and invasion by miR-145, miR-133a and miR-133b expression in gastric cancer cell lines (A: SGC7901, B: MKN45, C: BCG823). The
miR-145, miR-133a and miR-133b mimics inhibited cell migration and invasion in SGC7901, MKN45 and BCG823 cells compared with negative control oligonucleotide. NC,
negative control. Data are presented as means ± S.D. from three independent experiments. ⁄P < 0.05.
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in cancer tissues than in normal tissues. Down-regulation of
these miRNAs was also found in gastric cancer cell lines
SGC7901, MKN45 and BCG823 compared with human gastric
mucosal epithelial cell line GES-1 (Fig. 1B). These results sug-
gested that miR-145, miR-133a and miR-133b might play impor-
tant roles in gastric cancer progression by acting as suppressor
gene.
3.2. Overexpression of miR-145, miR-133a and miR-133b inhibit
gastric cancer cell proliferation, migration and invasion
To examine the role of miR-145, miR-133a and miR-133b in the
proliferation of gastric cancer cells, we conducted CCK8 assaysFig. 4. Regulation of cell cycle distribution by miR-145, miR-133a and miR-133b expres
miR-145, miR-133a, miR-133b and negative control oligonucleotide and then subjected
145, miR-133a and miR-133b could induce cell cycle G1 arrest. NC, negative control. ⁄Pwith transfected miR-145, miR-133a and miR-133b in SGC7901,
MKN45 and BCG823 cell lines, respectively. The results showed
that restoration of each miRNA signiﬁcantly suppressed cell prolif-
eration in the three cell lines (Fig. 2).
To determine whether miR-145, miR-133a and miR-133b could
regulate human gastric cancer cell migration and invasion, we per-
formed migration and invasion assays in gastric cancer cell lines
SGC7901, MKN45 and BCG823. MiR-145, miR-133a, miR-133b and
negative control oligonucleotide were transiently transfected in
these cells. As expected, ectopic expression of miR-145, miR-133a
and miR-133b signiﬁcantly decreased the migration and invasion
capability in all cell lines (Fig. 3). The observations indicated that
miR-145, miR-133a and miR-133b were negative regulators of
gastric cancer migration and invasion.sion. Gastric cancer cell lines SGC7901, MKN45 and BCG823 were transfected with
to ﬂow cytometric analysis of cell cycle distribution. The results showed that miR-
< 0.05.
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cycle of gastric cancer cells
Flow cytometry was executed to determine the effects of miR-
145, miR-133a and miR-133b on cell cycle alterations. As shown
in Fig. 4, over-expression of miR-145, miR-133a and miR-133b in-
duced G1 cell cycle arrest in all gastric cell lines. Meanwhile, the
cells arrested in S phase were highly increased.
3.4. Sp1 is a target gene of miR-145, miR-133a and miR-133b
A public database (TargetScan, available at http://www.target-
scan.org) predicted that Sp1, a protein which can mediate cell
cycle, migration and invasion, is a direct target gene of miR-145,Fig. 5. Sp1 is a target of miR-145, miR-133a and miR-133b. (A) Western blot. Expressio
gastric cancer cell lines SGC7901, MKN45 and BCG823. (B) Luciferase assay. Co-trans
luciferase reporter activity in 293T cells. Co-transfection of mutant type Sp1 30UTR an
negative control. ⁄P < 0.05.miR-133a and miR-133b. The potential binding capability of Sp1
30-UTR with these miRNAs was also predicted by the public data-
base mentioned above. Fig. 5A showed that in all three gastric cell
lines, ectopic expression of miR-145, miR-133a and miR-133b de-
creased Sp1 protein expression. To further conﬁrm that Sp1 is a di-
rect target for these miRNAs, we performed luciferase reporter
assays in human embryonic kidney cell line HEK293T. As illus-
trated in Fig. 5B, transfection of miR-145, miR-133a and miR-
133b signiﬁcantly decreased the Sp1 30-UTR luciferase reporter
activity compared with the negative control. Moreover, this effect
was abolished when the nucleotides in seed binding sites of the
Sp1 30-UTR were mutated. These results suggested that Sp1 was
a target gene of these miRNAs.n of miR-145, miR-133a and miR-133b could inhibit expression of Sp1 protein in
fection of wild type Sp1 30UTR and miR-145, miR-133a and miR-133b decreased
d miRNAs showed no signiﬁcant difference. Wt, wild type; Mut, mutant type. NC,
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Previous study demonstrated that strong Sp1 expression was
more frequently observed in human gastric cancer tissues rather
than normal gastric tissue specimens [17–19]. In our study, Sp1
expression in gastric cancer cells was analyzed by Western blot
and immunoﬂuorescence assay. As shown in Fig. 6A, Sp1 is over-
expressed in SGC7901, MKN45 and BCG823 compared with GES-
1. Consistent with this, immunoﬂuorescence staining of Sp1 was
detected in SGC7901, MKN45 and BCG823 (Fig. 6B).
3.6. MiR-145, miR-133a and miR-133b down-regulate the expression
of MMP-9 and Cyclin D1 via decreasing Sp1 expression in gastric
cancer cells
Previous studies indicated that Sp1 transcription factor could
regulate the expression of multiple genes, including MMP-9 and
Cyclin D1 [20–23]. To conﬁrm whether Sp1 participate in the tran-
scriptional regulation of MMP-9 and Cyclin D1 in gastric cancer,
the expression of Sp1 in SGC7901, MKN45 and BCG823 cells were
knocked down by transfection with small-interfering RNA (siRNA).
Western blot indicated that knock down of Sp1 resulted in a
decrease in the expression of MMP-9 and Cyclin D1 (Fig. 7A). To
further investigate the role miR-145, miR-133a and miR-133b
played in Sp1-induced decrease of migration, invasion and cellFig. 6. Expression of Sp1 in gastric cancer cell lines SGC7901, MKN45 and BCG823. (A
MKN45 and BCG823 compared with gastric mucosal epithelial cell line GES-1. (B) Immun
stained with FITC and DAPI, respectively. Column 4 is the merged image. Immunoﬂuore
Sp1 localized mainly in nucleus. ⁄P < 0.05.cycle progression, these miRNA mimics were transfected into gas-
tric cancer cells. We found that the expression of MMP-9 and Cy-
clin D1 were down-regulated in transfected cells (Fig. 7B). The
observation revealed that miR-145, miR-133a and miR-133b atten-
uated the expression of MMP-9 and Cyclin D1 via or partly by
decreasing Sp1 expression, thus inhibiting the migration, invasion
and cell cycle progression.
4. Discussion
It is widely accepted that miRNA dysregulation occurs in gastric
cancer as well as other cancers and contributes to carcinogenesis
and tumor progression. We analyzed several types of cancer tis-
sues to ﬁnd out differentially expressed miRNAs (data is unpub-
lished and further research is still carrying on by our team).
Combination with information from published studies and bioin-
formatic analysis, we found that miR-145, miR-133a and miR-
133b were down-regulated in gastric cancer tissues and cell lines.
Interestingly, public algorithm programs as previously described
predicted that Sp1 is a putative co-target gene for the above
miRNAs.
Sp1 is recognized as a transcriptional activator involved in al-
most all cellular processes in mammalian cells. The increase in
Sp1 transcriptional activity was observed in many cancers and
neurodegenerative disorders. SinceWang et al. [17] ﬁrstly reported) Western blot. Sp1 protein is over-expressed in gastric cancer cell lines SGC7901,
oﬂuorescence assay. Column 1 is the image of bright ﬁeld. Columns 2 and 3 are cells
scence in gastric cancer cell lines SGC7901, MKN45 and BCG823 demonstrated that
Fig. 7. Regulation of gene expression by ectopic expression of miR-145, miR-133a and miR-133b. (A) Western blot showed that knock down of Sp1 resulted in a decrease in
the expression of MMP-9 and Cyclin D1. (B) SGC7901, MKN45 and BCG823 cells were transfected with miR-145, miR-133a and miR-133b and then subjected to Western blot
analysis. The results showed that expression of MMP-9 and Cyclin D1 were down-regulated in transfected cells. NC, negative control. ⁄P < 0.05.
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number of studies have been published to describe the role of
Sp1 in gastric cancer. These studies showed that abnormally acti-
vated Sp1 expression represented a potential risk for poor progno-
sis, such as high risk of nodal metastases, and directly contributed
to gastric cancer development and progression [17–19].
However, the underlying mechanisms have not been clearly
elucidated. Investigations demonstrated that Sp1 expression was
inﬂuenced by many stimuli like hypoxia, acidosis or over-expres-
sion of free radicals [19,24]. Recently, it has been revealed that dys-
regulated miRNAs contributed to cancer initiation, development
and prognosis by regulating various genes at the post-transcrip-
tional level. And a cluster of miRNAs determining the regulation
of Sp1 expression has been noticed. Guo et al. found that miR-22
could act as tumor suppressor by targeting the Sp1 gene and could
inhibit gastric cancer cell migration and invasion [25]. Sp1 also
contained a binding site for miR-375 at 30-UTR and was negatively
regulated by miR-375, consequently decreasing cell malignant
behaviors [12]. Furthermore, Mao et al. reported that microR-330
inhibited cell motility by down-regulating Sp1 in prostate cancer
cells [26]. In the present study, we found that Sp1 expression
was signiﬁcantly decreased by over-expressed miR-145, miR-133a
and miR-133b. Luciferase activity assay conﬁrmed that the
30-UTR of Sp1 mRNA contains binding sites for these miRNAs.
The dysregulated miRNAs investigated in our study were con-
sistent with other studies. Reportedly, miR-133a and miR-133b
could inhibit cell proliferation, migration and invasion in bladdercancer [27] and prostate cancer [28] by targeting the epidermal
growth factor receptor (EGFR). A high-throughput screen identiﬁed
that miR-133a and miR-133b could decrease lung cancer cell sur-
vival by activating caspase-3/7-dependent apoptotic pathways
and inducing cell cycle arrest in S phase [29]. Suppressive role of
miR-133a could also be found in esophageal squamous cell carci-
noma [30], ovarian cancer [31], colorectal cancer [32] and so on.
As a prognostic marker, miR-133b could inhibit the progression
of colorectal cancer by regulation of CXCR4 [33]. For miR-145, a
low expression was associated with advanced clinical stage, lymph
node metastasis, larger tumour diameter and shorter disease-free
survival in prostate cancer patients [34] and small cell carcinoma
of the cervix [35]. MiR-145 could act as tumor suppressor in vari-
ous cancers, such as esophageal squamous cell carcinoma [36], oral
cancer [37], glioma [38], renal cell carcinoma [39] and so on. Over-
expression of miR-145 could also increase the sensitivity of vemu-
rafenib in drug-resistant colon cancer cell [40]. MiR-145 could also
be used as a diagnostic biomarker in pancreatic cancer [41]. Our
current data showed that down-regulated miR-145, miR-133a,
miR-133b blocked G1-to-S cell-cycle transition, inhibited cell pro-
liferation, migration and invasion in vitro. At the molecular level,
the above cell malignant behaviors were inhibited by decreased
expression of Cyclin D1 and MMP-9. Cyclin D1 can promote cell cy-
cle progression through activation of Cyclin-dependent kinase 4
(Cdk4)/Cdk6 [42], which reaches maximum activity in G1 period,
promoting cell cycle transition from G1 to S phase [43]. MMP-9
is a zinc-dependent endopeptidase that efﬁciently degrade the
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branes (BM) [44]. It is involved in many pathological processes
such as inﬂammation, and neural and vascular degenerative dis-
eases [45–47]. As an important regulator of tumor cell migration
and invasion, MMP-9 also plays an important role in the develop-
ment and progression of cancer. According to the data from the
UCSC database (http://genome.ucsc.edu) and previous studies
[20,21,23], Cyclin D1 and MMP-9 could be activated by transcrip-
tion factor Sp1. Taken together, our results suggested that aberrant
expression of miR-145, miR-133a and miR-133b participated in
progression of gastric cancer via decreasing the Sp1 expression
and its downstream molecules MMP-9, Cyclin D1.
In conclusion, we found that miR-145, miR-133a and miR-133b
were down-regulated in gastric cancer tissues and gastric cancer
cells. The loss of miR-145, miR-133a and miR-133b promoted cell
proliferation, migration, invasion and cell cycle progression
in vitro. Sp1 contains a binding site for these miRNAs at 30-UTR
and was a direct target of them. MiR-145, miR-133a and miR-
133b inhibited cell malignant behaviors by negatively regulating
Sp1 and its downstream molecules MMP-9, Cyclin D1. Taken to-
gether, in this report we demonstrated for the ﬁrst time that,
miR-145, miR-133a and miR-133b inhibited cell proliferation,
migration, invasion and cell cycle progression via or partly through
decreasing the Sp1 expression and its downstream molecules
MMP-9, Cyclin D1. Thus both these miRNAs and their target gene
Sp1 might be therapeutic targets for gastric cancer.
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